BioWorld

Dec. 29, 2005

Targacept, AstraZeneca Enter TC-1734 Deal For Up To $300M

Signing a deal worth up to $300 million for one product - and possibly more if others come into play - Targacept Inc. partnered worldwide rights to its Phase II cognitive disorder drug, TC-1734, with AstraZeneca plc. (BioWorld Today) Read More

FDA Approves Celgene's Revlimid On Phase II Data

Muscle Growth Agent Blocks Myostatin, But Not Just That

Discovery Labs Paying $16M For Manufacturing Operations

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...